ZNTL (STOCKS)
Zentalis Pharmaceuticals, Inc. Common Stock
$3.780000
+0.030000 (+0.80%)
Prev close: $3.750000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Biotechnology
- CEO
- Julia Marie Eastland
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $269.80M
- Employees
- 166
- P/E (TTM)
- -2.16
- P/B (TTM)
- 1.46
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
4
Strong Buy
5
Buy
6
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Mar 2026 (Q1)
|
$-0.50 | $-0.49 | -0.0139 | -2.86% |
|
Dec 2025 (Q4)
|
$-0.50 | $-0.59 | +0.0906 | +15.34% |
|
Sep 2025 (Q3)
|
$-0.37 | $-0.54 | +0.1684 | +31.28% |
|
Jun 2025 (Q2)
|
$-0.37 | $-0.59 | +0.2230 | +37.61% |
Financial Statements
| Revenues | $0.00 |
| Operating Expenses | $145.04M |
| Research and Development | $108.76M |
| Other Operating Expenses | $36.28M |
| Operating Income/Loss | -$145.04M |
| Income/Loss From Continuing Operations After Tax | -$124.13M |
| Income/Loss From Continuing Operations Before Tax | -$123.57M |
| Income Tax Expense/Benefit | $562.00K |
| Net Income/Loss | -$124.13M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$124.13M |
| Net Income/Loss Available To Common Stockholders, Basic | -$124.13M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | -$1.73 |
| Diluted Earnings Per Share | -$1.73 |
| Basic Average Shares | 214,326,000 |
| Diluted Average Shares | 214,326,000 |
| Assets | $253.07M |
| Current Assets | $218.10M |
| Noncurrent Assets | $34.97M |
| Fixed Assets | $2.65M |
| Other Non-current Assets | $32.32M |
| Liabilities | $70.39M |
| Current Liabilities | $35.24M |
| Accounts Payable | $7.38M |
| Wages | $4.72M |
| Other Current Liabilities | $23.14M |
| Noncurrent Liabilities | $35.15M |
| Equity | $182.68M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $182.68M |
| Liabilities And Equity | $253.07M |
| Net Cash Flow From Operating Activities | -$125.57M |
| Net Cash Flow From Operating Activities, Continuing | -$125.57M |
| Net Cash Flow From Investing Activities | $121.16M |
| Net Cash Flow From Investing Activities, Continuing | $121.16M |
| Net Cash Flow From Financing Activities | -$5.59M |
| Net Cash Flow From Financing Activities, Continuing | -$5.59M |
| Net Cash Flow | -$10.00M |
| Net Cash Flow, Continuing | -$10.00M |
| Comprehensive Income/Loss | -$124.54M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$124.54M |
| Other Comprehensive Income/Loss | -$35.76M |
| Other Comprehensive Income/Loss Attributable To Parent | -$408.00K |